CINECA IRIS Institutional Research Information System

CREMOLINI, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.481
EU - Europa 5.211
AS - Asia 3.249
AF - Africa 266
SA - Sud America 12
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 6
Totale 24.235
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.231
IT - Italia 2.143
CN - Cina 1.506
SG - Singapore 1.006
SE - Svezia 817
BG - Bulgaria 626
DE - Germania 436
GB - Regno Unito 297
VN - Vietnam 294
CA - Canada 247
TR - Turchia 186
FI - Finlandia 185
RU - Federazione Russa 161
CI - Costa d'Avorio 151
HK - Hong Kong 119
UA - Ucraina 115
FR - Francia 108
AT - Austria 91
IN - India 73
PL - Polonia 55
CH - Svizzera 49
SN - Senegal 48
NG - Nigeria 45
NL - Olanda 34
BE - Belgio 31
JP - Giappone 18
CZ - Repubblica Ceca 12
KR - Corea 12
BJ - Benin 10
ES - Italia 10
BR - Brasile 8
GR - Grecia 8
AU - Australia 7
ID - Indonesia 7
IE - Irlanda 7
EU - Europa 6
IR - Iran 6
LT - Lituania 6
TW - Taiwan 6
MY - Malesia 5
EG - Egitto 4
IL - Israele 4
LU - Lussemburgo 4
DK - Danimarca 3
NZ - Nuova Zelanda 3
RO - Romania 3
TN - Tunisia 3
AR - Argentina 2
CY - Cipro 2
KE - Kenya 2
LV - Lettonia 2
NO - Norvegia 2
SK - Slovacchia (Repubblica Slovacca) 2
AG - Antigua e Barbuda 1
CL - Cile 1
CO - Colombia 1
CR - Costa Rica 1
DZ - Algeria 1
EE - Estonia 1
KH - Cambogia 1
KZ - Kazakistan 1
MX - Messico 1
NP - Nepal 1
PH - Filippine 1
PT - Portogallo 1
RE - Reunion 1
SI - Slovenia 1
SM - San Marino 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 24.235
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.995
Fairfield 1.614
Ann Arbor 1.424
Houston 1.274
Santa Clara 1.273
Chandler 1.087
Ashburn 771
Seattle 709
Sofia 625
Wilmington 590
Cambridge 586
Milan 550
Shanghai 529
New York 481
Singapore 446
Boardman 384
Princeton 295
Beijing 290
Lawrence 283
Medford 235
Ottawa 226
Florence 173
Pisa 162
Dearborn 152
Abidjan 151
Des Moines 145
Jacksonville 138
Nanjing 128
Serra 119
Hong Kong 106
Istanbul 101
Dong Ket 97
Rome 93
Vienna 89
London 86
San Diego 83
Izmir 80
Düsseldorf 77
Ogden 74
Cascina 69
Bremen 60
Redwood City 59
Lancaster 55
Warsaw 54
Nanchang 50
Dakar 48
Bern 46
Genoa 46
Lagos 45
Seacroft 41
Kunming 39
Shenyang 39
Boulder 38
Lappeenranta 35
Fuzhou 34
Frankfurt am Main 33
Los Angeles 32
Jüchen 31
Norwalk 31
Hebei 30
Brussels 28
Marseille 27
Hefei 25
Turin 25
Changsha 23
Naples 23
Gargallo 21
Kent 21
Munich 19
Guangzhou 18
Phoenix 17
Tianjin 17
Washington 17
Dallas 16
Hyderabad 16
Jiaxing 16
Positano 15
Pune 15
Quanzhou 15
Verona 14
Falls Church 13
Helsinki 13
Padova 12
Livorno 11
Cotonou 10
Hangzhou 10
Jinan 10
Lucca 10
Palermo 10
Toronto 10
Auburn Hills 9
Bologna 9
Chengdu 9
Capannori 8
Chicago 8
Grafing 8
San Francisco 8
Shenzhen 8
Zhengzhou 8
Groningen 7
Totale 19.215
Salva come PNG Salva come JPEG
Nome #
OUTCOME OF SECOND-LINE TREATMENT AFTER FIRST-LINE CHEMOTHERAPY WITH THE GONO FOLFOXIRI REGIMEN. 167
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 160
Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients 160
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 154
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 148
KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 148
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis 143
TAS-102 for the treatment of metastatic colorectal cancer 143
KRAS codon 61, 146 and BRAF V600E mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer 138
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 137
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer 136
Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 135
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 135
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 134
BRAF V600E mutation and amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 133
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 130
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 130
null 129
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials 129
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 128
null 127
Case-report: folfoxiri plus bevacizumab in "poor-risk" liver-only metastatic colorectal cancer: case report and state-of-the-art. 126
Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients 125
Prevention and management of adverse events related to regorafenib 123
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. 122
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 122
BRAF V600E mutation and amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (MCRC) patients 121
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 121
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 120
Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer 119
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 119
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials 118
VEGF gene polymorphisms in the prediction of benefit from first-line folfiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 117
Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer 116
VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 115
Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients 115
KRAS and BRAF mutational analyses in a phase II trial of first-line folfoxiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 114
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 114
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: Results from TRIBE and FIRE3 trials 114
Folfoxiri plus bevacizumab as first-line treatment in braf mutant metastatic colorectal cancer. 114
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 114
FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus beva s first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial. 113
KRAS and BRAF genotyping of synchronous colorectal carcinomas. 113
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle 112
null 111
BRAF-mutated metastatic colorectal cancer between past and future 111
First-line therapy for mCRC-the influence of primary tumour location on the therapeutic algorithm 111
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 111
Histopathologic response to FOLFOXIRI plus bevacizumab of liver metastases from colorectal cancer. 110
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice 110
Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts). 109
ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer 108
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 108
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial 108
null 108
BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 107
Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram 107
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable 107
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients 106
Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in K-RAS wild-type metastatic colorectal cancer (mCRC) patients 105
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest 105
Do we need biopsies of metastases for colorectal cancer patients? 104
KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab. 104
High activity and resection rate in molecularly selected patients with unresectable metastatic colorectal cancer (MCRC) treated with panitumumab (P) and folfoxiri as first-line therapy : a phase II study. 104
Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP”trial by the Gruppo Oncologico Nord Ovest (GONO). 103
Risk for developing brain metastases from colorectal cancer in long-term survivors with lung metastases and KRAS mutations. 102
Folfoxiri in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 102
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study 102
Circulating tumor DNA analysis in colorectal cancer: From dream to reality 102
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 101
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer 101
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer 101
Histopathological response to folfoxiri plus bevacizumab of liver metastases from colorectal cancer. 100
Polymorphisms in genes involved in EGFR turnover are predictive for cetuximab efficacy in colorectal cancer 100
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab 100
Host genetic variants in the Insulin Growth Factor Binding Protein-3 impact on servival of patients with advanced gastric cancer treated with palliative chemotharapy 99
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: Meta-analytical estimation and implications for therapeutic strategies. 99
Prognostic significance of KRAS mutation rate in metastatic colorectal cancer patients. 99
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer 99
Prevention of capecitabine toxicity using a 5-FU test dose 99
Genetic variants of kinases suppressors of ras in KRAS-BREF wild-type metastatic colorectal cancer patients treated with cetuximab and irinotecan. 99
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 99
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib 99
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer 98
null 98
A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO). 98
Preliminary results from a phase II study of panitumumab (P) in combination with folfoxiri as first-line treatment of molecularly selected metastatic colorectal cancer (MCRC) patients (PTS) 97
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients 97
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3 97
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. 97
Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts). 96
Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer 96
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 96
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer 95
Biomarkers and response to bevacizumab--letter 95
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells 95
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study) 94
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis 94
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis 93
Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: Challenging drug label to light up new hope 93
Totale 11.340
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.524
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.524
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.911 0 0 0 0 0 0 457 351 422 285 291 105
2020/20212.136 150 143 74 79 118 321 109 143 286 138 133 442
2021/20222.601 36 91 40 73 464 478 52 82 184 172 162 767
2022/20233.384 450 433 219 330 336 418 43 210 597 34 281 33
2023/20243.584 291 330 509 233 474 516 264 97 177 134 202 357
2024/20253.508 167 400 171 461 900 1.200 209 0 0 0 0 0
Totale 25.078